Entrada Therapeutics Q1 net loss beats analyst estimates

Entrada Therapeutics

07/05/2026 12:17

Overview

U.S. biopharma firm's Q1 net loss narrowed versus analyst expectations

Q1 collaboration revenue fell sharply due to winding down of Vertex partnership

Company reported positive topline results from Duchenne muscular dystrophy trial

Outlook

Entrada expects to report ELEVATE-45-201 Cohort 1 data in mid-2026

Company expects to report ELEVATE-44-201 open-label and Cohort 2 data by year-end 2026

Entrada expects cash runway into Q3 2027

Result Drivers

COLLABORATION REVENUE DROP - Revenue fell due to substantial completion of Vertex partnership research activities

HIGHER R&D SPEND - Increased R&D expenses driven by additional costs for DMD programs

POSITIVE CLINICAL DATA - Announced favorable safety, tolerability and early functional benefit from ELEVATE-44-201 Cohort 1 in DMD

Company press release: ID:nGNXD5N1w

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$875,000
Q1 Net Income
Beat
-$39.72 mln
-$45.10 mln (7 Analysts)
Q1 Income From Operations
-$42.30 mln
Q1 Operating Expenses
$43.18 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)